WHO ICTRP trial
Efficacy and safety of telitacicept in the treatment of primary IgA nephropathy…
ChiCTR2400083991 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR2400083991 |
|---|---|
| Public title | Efficacy and safety of telitacicept in the treatment of primary IgA nephropathy: a prospective cohort study |
| Scientific title | Efficacy and safety of telitacicept in the treatment of primary IgA nephropathy: a prospective cohort study |
| Primary sponsor | The Second Hospital of Shanxi Medical University |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Observational study |
| Countries | China |
| Conditions | IgA nephropathy |
| Interventions | Telitacicept group:None;Treatment with other immunosuppressants standard protocols:None |
| Registration date | May 8, 2024 |
| Target size | Telitacicept group:50;Treatment with other immunosuppressants standard… |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: